PetMed Express (PETS) Projected to Post Quarterly Earnings on Tuesday

Key Points

• PetMed Express is set to release its Q4 2025 earnings on August 5th, with analysts predicting a loss of ($0.02) per share and revenue of $51.10 million.
• Recent trading data shows PetMed Express stock down to $3.31, with a market cap of $68.28 million and a significant decrease in insider ownership following sales by CEO Sandra Yvette Campos.
• Goldman Sachs recently increased its holdings in PetMed Express by 59.3%, while institutional investors control 73.33% of the company's stock.

PetMed Express (NASDAQ:PETS - Get Free Report) is expected to be announcing its Q4 2025 earnings results before the market opens on Tuesday, August 5th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $51.10 million for the quarter.

PetMed Express Trading Up 1.1%

PETS traded up $0.04 during trading hours on Friday, hitting $3.16. The company's stock had a trading volume of 61,324 shares, compared to its average volume of 193,833. The business's 50-day moving average price is $3.53 and its 200-day moving average price is $3.90. PetMed Express has a 12 month low of $2.90 and a 12 month high of $6.85. The stock has a market cap of $65.18 million, a price-to-earnings ratio of 316.32 and a beta of 0.78.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on PETS shares. Morgan Stanley reduced their price target on shares of PetMed Express from $3.50 to $3.20 and set an "underweight" rating on the stock in a research report on Thursday, April 17th. Wall Street Zen upgraded shares of PetMed Express from a "sell" rating to a "hold" rating in a research report on Saturday, July 26th.

Insider Buying and Selling

In other news, major shareholder Silvercape Investments Ltd acquired 31,701 shares of the company's stock in a transaction on Thursday, July 17th. The stock was bought at an average cost of $3.15 per share, with a total value of $99,858.15. Following the completion of the purchase, the insider directly owned 2,342,931 shares of the company's stock, valued at $7,380,232.65. This represents a 1.37% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have acquired 59,484 shares of company stock worth $194,898 over the last ninety days. 1.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in PetMed Express stock. Goldman Sachs Group Inc. boosted its position in shares of PetMed Express, Inc. (NASDAQ:PETS - Free Report) by 59.3% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 33,209 shares of the company's stock after buying an additional 12,360 shares during the quarter. Goldman Sachs Group Inc. owned 0.16% of PetMed Express worth $139,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 73.33% of the company's stock.

About PetMed Express

PetMed Express, Inc, together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and household pet supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.